Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
Date:1/31/2008

e made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litig
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Hologic Announces First Quarter Fiscal 2008 Operating Results
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Genelabs Technologies, Inc. Announces Resignation of President and CEO
9. CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
10. BioHorizons Announces Agreement to Purchase Implant Logic Systems
11. AlphaVax Announces New CMV Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... ( www.aapc.com ) announced its 2012 medical coding books ... previous year. Prices have been reduced more than 55 percent over ... reduction was to benefit our more than 100,000 members, non-members of ... Starynskaya, coding books department manager for of AAPC. ...
... (NASDAQ: ITMN ) today announced that it will ... open of the U.S. markets on Thursday, April 28, 2011. ... InterMune at 8:30 a.m. Eastern time that same day. ... 706-643-9223 (international), conference ID# 62213806.  To access the webcast, please ...
... Eigen is the proud recipient of two grant awards ... U.S. Department of Health & Human Services. QTDP tax credits ... (IRC), enacted as part of the Patient Protection and Affordable ... $244,000 award for each grant awarded in October, 2010, and ...
Cached Biology Technology:AAPC Lowers Prices on Medical Coding Books, Again 2Eigen Receives Two Grant Awards from U.S. Department of Health & Human Services 2
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... select partners? Darwin,s initial idea that the fittest males ... likely to secure partners has represented a cornerstone of evolutionary ... 1871. Darwin proposed that secondary sexual characteristics enabled females ... best for every female. This male would be the ...
... three percent (n=181) of patients in the study cohort ... their arthritis developed a first cancer within nine years ... of arthritis. The nine year follow-up study conducted ... ((RR)=1.03 (95%confidence interval 0.82-1.30)) was not increased in patients ...
... Scientists from the University of Warwick have discovered ... be ,ultra-bad, leading to increased risk of heart disease. ... heart disease particularly in people with type 2 diabetes ... British Heart Foundation (BHF), found that ,ultrabad, cholesterol, called ...
Cached Biology News:The importance of 'inner values' -- female sparrows test the genetic make-up of their mates 2Arthritis patients taking newer treatments do not have an overall increased cancer risk 2Super-sticky 'ultra-bad' cholesterol revealed in people at high risk of heart disease 2
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
... Ambions MAXIscript In Vitro Transcription Kits synthesize ... x 10 9 cpm/g. High specific ... ribonuclease protection assays, in situ hybridization, and ... used for the synthesis of modest amounts ...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Request Info...
Biology Products: